Uncategorized

argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that it will host a conference call and audio webcast on Thursday, May 4, 2023 at 2:30 pm CET to discuss its first quarter 2023 financial results and provide a business update.

Scott Arnold, executive vice president and chief information officer of Tampa General Hospital, has been named a top health care information technology leader by Becker’s Hospital Review on its 2023 “CIOs to Know” list.

Dizal announced that multiple clinical data of its two leading assets – sunvozertinib and golidocitinib have been selected for presentations at the 2023 ASCO, June 2-6, 2023 in Chicago.

Genomma Lab Internacional, S.A.B. de C.V., announced its results for the first quarter ended March 31, 2023.

Thanks to the strong interest from clinicians and patients, we were able to swiftly dose the first patients in the phase 2a part of the combination study with fostrox and Lenvima® in HCC after completed dose escalation.

Seres Therapeutics, Inc. and Nestlé Health Science announced the U.S. Food and Drug Administration approval of VOWSTTM, formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibacterial treatment for recurrent CDI.

Antengene Corporation Limited announced that the results of the Phase I/II TORCH-2 study will be presented as a poster discussion during the American Society for Clinical Oncology Annual Meeting, taking place from June 2nd to 6th at the McCormick Place Convention Center in Chicago, IL.

Exploratory feasibility studies of amorphOX® initiated in collaboration with two international biopharmaceutical and vaccine companies.

Swedish Orphan Biovitrum AB announced its report for the first quarter of 2023

The operator posted increases in acute care and behavioral volumes while tempering labor costs.